Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome

Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome

US Patent 6599927 · Granted Jul 29, 2003

Estimated economic value: $12,248,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

[6R]—MTHF—an efficient folate alternative in 5-fluorouracil based chemotherapy2021
[6R]-MTHF multiple bolus administration in 5-fluorouracil based chemotherapy2019
Use for budesonide and formoterol2013
Process for the preparation of esomeprazole non-salt form2012
Use for budesonide and formoterol2011
Inhaler with powder dislodging member2010
Inhalation device2010
Compounds2005
Compounds useful as antibacterial agents2004
Inhalation device2003
Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps2002
Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps2002